-
1
-
-
0030444894
-
A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy
-
Abraham R, Basser RL, Green MD. A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy. Drug Saf 1996;15:406-29.
-
(1996)
Drug Saf
, vol.15
, pp. 406-429
-
-
Abraham, R.1
Basser, R.L.2
Green, M.D.3
-
2
-
-
0027343763
-
Strategies for prevention of anthracycline cardiotoxicity
-
Basser RL, Green MD. Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev 1993;19:57-77.
-
(1993)
Cancer Treat Rev
, vol.19
, pp. 57-77
-
-
Basser, R.L.1
Green, M.D.2
-
3
-
-
0032563825
-
Current concepts: Doxorubicin induced cardiomyopathies
-
Singal PK, Iliskovic N. Current concepts: doxorubicin induced cardiomyopathies. N Engl J Med 1998;339:900-5
-
(1998)
N Engl J Med
, vol.339
, pp. 900-905
-
-
Singal, P.K.1
Iliskovic, N.2
-
4
-
-
0025059659
-
Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: Relationship with binding mode and anti-tumour activity
-
Denny WA, Wakelin LP. Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and anti-tumour activity. Anticancer Drug Des 1990;5:189-200.
-
(1990)
Anticancer Drug Des
, vol.5
, pp. 189-200
-
-
Denny, W.A.1
Wakelin, L.P.2
-
5
-
-
0022340391
-
Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids
-
Lown JW, Morgan AR, Yen SF, Wang YH, Wilson WD. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry 1985;24:4028-35.
-
(1985)
Biochemistry
, vol.24
, pp. 4028-4035
-
-
Lown, J.W.1
Morgan, A.R.2
Yen, S.F.3
Wang, Y.H.4
Wilson, W.D.5
-
6
-
-
0028822554
-
Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells
-
Hazlehurst LA, Krapcho AP, Hacker MP. Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Biochem Pharmacol 1995;50:1087-94.
-
(1995)
Biochem Pharmacol
, vol.50
, pp. 1087-1094
-
-
Hazlehurst, L.A.1
Krapcho, A.P.2
Hacker, M.P.3
-
7
-
-
0031012073
-
Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones
-
de Isabella P, Palumbo M, Sissi C, Carenini N, Capranico G, Menta E, et al. Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones. Biochem Pharmacol 1997;53:161-9.
-
(1997)
Biochem Pharmacol
, vol.53
, pp. 161-169
-
-
De Isabella, P.1
Palumbo, M.2
Sissi, C.3
Carenini, N.4
Capranico, G.5
Menta, E.6
-
8
-
-
0035746666
-
BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity
-
Beggiolin G, Crippa L, Menta E, Manzotti C, Cavalletti E, Pezzoni G, et al. BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 2001;87:407-16.
-
(2001)
Tumori
, vol.87
, pp. 407-416
-
-
Beggiolin, G.1
Crippa, L.2
Menta, E.3
Manzotti, C.4
Cavalletti, E.5
Pezzoni, G.6
-
9
-
-
0018566889
-
Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse
-
Bertazzoli C, Bellini O, Magrini U, Tosana MG. Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep 1979;63:1877-83.
-
(1979)
Cancer Treat Rep
, vol.63
, pp. 1877-1883
-
-
Bertazzoli, C.1
Bellini, O.2
Magrini, U.3
Tosana, M.G.4
-
10
-
-
0034988022
-
Phase I study of BBR 2778, a new aza-anthracenedione in advanced or refractory non-Hodgkin's lymphoma
-
Borchmann P, Schnell R, Knippertz R, Staak JO, Camboni GM, Bernareggi A, et al. Phase I study of BBR 2778, a new aza-anthracenedione in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001;12:661-7.
-
(2001)
Ann Oncol
, vol.12
, pp. 661-667
-
-
Borchmann, P.1
Schnell, R.2
Knippertz, R.3
Staak, J.O.4
Camboni, G.M.5
Bernareggi, A.6
-
11
-
-
0035136099
-
A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies
-
Faivre S, Raymond E, Boige V, Gatineau M, Buthaut X, Rixe O, et al. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin Cancer Res 2001;7:43-50.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 43-50
-
-
Faivre, S.1
Raymond, E.2
Boige, V.3
Gatineau, M.4
Buthaut, X.5
Rixe, O.6
-
12
-
-
0033711725
-
A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly
-
Dawson LK, Jodrell DI, Bowman A, Rye R, Byrne B, Bernareggi A, et al. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur J Cancer 2000;36:2353-9.
-
(2000)
Eur J Cancer
, vol.36
, pp. 2353-2359
-
-
Dawson, L.K.1
Jodrell, D.I.2
Bowman, A.3
Rye, R.4
Byrne, B.5
Bernareggi, A.6
-
13
-
-
0032784783
-
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Air-lie House, Virginia, November 1997
-
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Air-lie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3835-3849
-
-
Harris, N.L.1
Jaffe, E.S.2
Diebold, J.3
Flandrin, G.4
Muller-Hermelink, H.K.5
Vardiman, J.6
-
14
-
-
0030883053
-
1997 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
-
American Society of Clinical Oncology
-
1997 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1997;15:3288.
-
(1997)
J Clin Oncol
, vol.15
, pp. 3288
-
-
-
15
-
-
0002207395
-
Grading of toxicity
-
Macdonald JHD, Mayer R, eds. Philadelphia, PA, USA. Lippincott
-
Macdonald J, Haller D, Mayer R. Grading of toxicity. In: Macdonald JHD, Mayer R, eds. Manual of Oncologic Therapeutics. Philadelphia, PA, USA. Lippincott, 1995.
-
(1995)
Manual of Oncologic Therapeutics
-
-
Macdonald, J.1
Haller, D.2
Mayer, R.3
-
16
-
-
0042449063
-
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
-
NCI Sponsored International Working Group
-
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1244
-
-
Cheson, B.D.1
Horning, S.J.2
Coiffier, B.3
Shipp, M.A.4
Fisher, R.I.5
Connors, J.M.6
-
17
-
-
0026763215
-
Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma
-
De Lord C, Newland AC, Linch DC, Vaughan Hudson B, Vaughan Hudson G. Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma. Hematol Oncol 1992;10:81-6.
-
(1992)
Hematol Oncol
, vol.10
, pp. 81-86
-
-
De Lord, C.1
Newland, A.C.2
Linch, D.C.3
Vaughan Hudson, B.4
Vaughan Hudson, G.5
-
18
-
-
0019997890
-
IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy
-
Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982;60:693-7.
-
(1982)
Blood
, vol.60
, pp. 693-697
-
-
Cabanillas, F.1
Hagemeister, F.B.2
Bodey, G.P.3
Freireich, E.J.4
-
19
-
-
0019813624
-
Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B
-
Cavalli F, Jungi WF, Nissen NI, Pajak TF, Coleman M, Holland JF. Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B. Cancer 1981;48:1927-30.
-
(1981)
Cancer
, vol.48
, pp. 1927-1930
-
-
Cavalli, F.1
Jungi, W.F.2
Nissen, N.I.3
Pajak, T.F.4
Coleman, M.5
Holland, J.F.6
-
20
-
-
12944259223
-
Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas
-
Groupe d'Etude des Lymphomes de I'Adulte
-
Casasnovas RO, Haioun C, Dumontet C, Gabarre J, Richard B, Lederlin P, et al. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de I'Adulte. Haematologica 2000;85:502-7.
-
(2000)
Haematologica
, vol.85
, pp. 502-507
-
-
Casasnovas, R.O.1
Haioun, C.2
Dumontet, C.3
Gabarre, J.4
Richard, B.5
Lederlin, P.6
-
21
-
-
0032784782
-
Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
-
Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3786-92.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3786-3792
-
-
Fossa, A.1
Santoro, A.2
Hiddemann, W.3
Truemper, L.4
Niederle, N.5
Buksmaui, S.6
-
22
-
-
0025970652
-
The evolving role of etoposide in the management of lymphomas and Hodgkin's disease
-
O'Reilly SE, Klimo P, Connors JM. The evolving role of etoposide in the management of lymphomas and Hodgkin's disease. Cancer 1991;67:271-80.
-
(1991)
Cancer
, vol.67
, pp. 271-280
-
-
O'Reilly, S.E.1
Klimo, P.2
Connors, J.M.3
-
23
-
-
0027369897
-
Pilot study and randomised trial of mitozantrone and ifosfamide for relapsed non-Hodgkin's lymphoma
-
Scotland and Newcastle Lymphoma group (SNLG) Working Party on Therapy
-
Prescott RJ, Leonard RC. Pilot study and randomised trial of mitozantrone and ifosfamide for relapsed non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma group (SNLG) Working Party on Therapy. Leuk Lymphoma 1993; 11:111-4.
-
(1993)
Leuk Lymphoma
, vol.11
, pp. 111-114
-
-
Prescott, R.J.1
Leonard, R.C.2
-
24
-
-
0031891979
-
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246
-
Press OW, LeBlanc M, O'Rourke TJ, Gagnet S, Chapman RA, Balcerzak SP, et al. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J Clin Oncol 1998; 16:574-8,
-
(1998)
J Clin Oncol
, vol.16
, pp. 574-578
-
-
Press, O.W.1
LeBlanc, M.2
O'Rourke, T.J.3
Gagnet, S.4
Chapman, R.A.5
Balcerzak, S.P.6
-
25
-
-
0035008043
-
Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma
-
Tulpule A, Rarick MU, Kolitz J, Bernstein J, Myers A, Buchanan LA, et al. Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann Oncol 2001;12:457-62.
-
(2001)
Ann Oncol
, vol.12
, pp. 457-462
-
-
Tulpule, A.1
Rarick, M.U.2
Kolitz, J.3
Bernstein, J.4
Myers, A.5
Buchanan, L.A.6
-
26
-
-
0035986759
-
Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: Results from a prospective phase II study
-
Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP, et al. Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica 2002; 87:822-7.
-
(2002)
Haematologica
, vol.87
, pp. 822-827
-
-
Martino, R.1
Perea, G.2
Caballero, M.D.3
Mateos, M.V.4
Ribera, J.M.5
De Oteyza, J.P.6
-
27
-
-
0032409240
-
DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide: An effective and well-tolerated new regimen for patients with relapsed lymphoma
-
Reiser M, Schnell R, Straub G, Borchmann P, Wilhelm M, Ubelacker R, et al. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide: an effective and well-tolerated new regimen for patients with relapsed lymphoma. Leuk Lymphoma 1998;31:359-66.
-
(1998)
Leuk Lymphoma
, vol.31
, pp. 359-366
-
-
Reiser, M.1
Schnell, R.2
Straub, G.3
Borchmann, P.4
Wilhelm, M.5
Ubelacker, R.6
-
28
-
-
0025957150
-
PARMA international protocol: Pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients)
-
Philip T, Chauvin F, Bron D, Guglielmi C, Hagenbeek A, Coiffier B, et al. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). Ann Oncol 1991;2 Suppl 1:57-64.
-
(1991)
Ann Oncol
, vol.2
, Issue.SUPPL. 1
, pp. 57-64
-
-
Philip, T.1
Chauvin, F.2
Bron, D.3
Guglielmi, C.4
Hagenbeek, A.5
Coiffier, B.6
-
29
-
-
0034329772
-
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH
-
Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000;18:3633-42.
-
(2000)
J Clin Oncol
, vol.18
, pp. 3633-3642
-
-
Gutierrez, M.1
Chabner, B.A.2
Pearson, D.3
Steinberg, S.M.4
Jaffe, E.S.5
Cheson, B.D.6
-
30
-
-
17144465163
-
Mantle cell lymphoma: Clinical features, treatment and prognosis of 94 patients
-
Oinonen R, Franssila K, Teerenhovi L, Lappalainen K, Elonen E. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998;34:329-36.
-
(1998)
Eur J Cancer
, vol.34
, pp. 329-336
-
-
Oinonen, R.1
Franssila, K.2
Teerenhovi, L.3
Lappalainen, K.4
Elonen, E.5
-
31
-
-
0029767924
-
Mitoxantrone: A review of its pharmacological properties and use in acute nonlymphoblastic leukaemia
-
Dunn CJ, Goa KL. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Drugs Aging 1996;9:122-47.
-
(1996)
Drugs Aging
, vol.9
, pp. 122-147
-
-
Dunn, C.J.1
Goa, K.L.2
-
32
-
-
0036248746
-
The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: An experimental study
-
Koutinos G, Stathopoulos GP, Dontas I, Perrea-Kotsarelis D, Couris E, Karayannacos PE, et al. The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study. Anticancer Res 2002; 22:815-20.
-
(2002)
Anticancer Res
, vol.22
, pp. 815-820
-
-
Koutinos, G.1
Stathopoulos, G.P.2
Dontas, I.3
Perrea-Kotsarelis, D.4
Couris, E.5
Karayannacos, P.E.6
|